Brentuximab vedotin (BV) is an anti-CD30 antibody drug conjugate that has established efficacy in relapsed/refractory Hodgkin and some T-cell lymphomas. This evidence concerns the gene TNFRSF8 and T-cell non-Hodgkin lymphoma.